SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

$CWBR
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Get the next $CWBR alert in real time by email
SC 13G/A 1 ea172596-13ga3cohen_cohbar.htm AMENDMENT NO. 3 TO SCHEDULE 13G

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G
(Amendment No. 3)*

 

Under the Securities Exchange Act of 1934

CohBar, Inc.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

19249J307

(CUSIP Number)

 

December 31, 2022

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 19249J307   SC 13G   Page 2 of 5

 

1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Pinchas Cohen
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a)     ☐

(b)     ☐

3.  

SEC USE ONLY
 

4.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States of America

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
  5.  

SOLE VOTING POWER

 

184,852(1)

  6.   SHARED VOTING POWER
 
0
  7.   SOLE DISPOSITIVE POWER
 
184,852(1)
  8.  

SHARED DISPOSITIVE POWER

 

0

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

184,852(1)
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)     ☐

 

11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.36%
12.   TYPE OF REPORTING PERSON (see instructions)

IN

 

1.Includes an aggregate of 3,195 shares issuable upon exercise of stock options exercisable within 60 days of the date hereof.

 

 

 

 

CUSIP No. 19249J307   SC 13G   Page 3 of 5

 

Item 1.

 

  (a) Name of Issuer
CohBar, Inc.
     
  (b)

Address of Issuer’s Principal Executive Offices
1455 Adams Drive

Menlo Park, CA 94025

 

Item 2.

 

  (a) Name of Person Filing
Pinchas Cohen
     
  (b)

Address of the Principal Office or, if none, residence
c/o CohBar, Inc.

1455 Adams Drive

Menlo Park, CA 94025

     
  (c) Citizenship
United States of America
     
  (d) Title of Class of Securities
Common Stock, par value $0.001 per share
     
  (e) CUSIP Number
19249J307

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
  (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
  (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

 

 

 

CUSIP No. 19249J307   SC 13G   Page 4 of 5

 

Item 4. Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a) Amount beneficially owned: 184,852*
       
  (b) Percent of class: 6.36%
       
  (c) Number of shares as to which the person has:
       
    (i) Sole power to vote or to direct the vote: 184,852*
       
    (ii) Shared power to vote or to direct the vote: 0
       
    (iii) Sole power to dispose or to direct the disposition of: 184,852*
       
    (iv) Shared power to dispose or to direct the disposition of: 0

 

* Includes an aggregate of 3,195 shares issuable upon exercise of stock options exercisable within 60 days of the date hereof.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable

 

Item 9. Notice of Dissolution of Group.

 

Not applicable

 

Item 10. Certification.

 

Not applicable

 

 

 

 

CUSIP No. 19249J307   SC 13G   Page 5 of 5

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

February 8, 2023

Date

   
 

/s/ Pinchas Cohen

Signature

   
 

Pinchas Cohen

Name

 

 

 

 

 

Get the next $CWBR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CWBR

DatePrice TargetRatingAnalyst
8/11/2021$5.00Speculative Buy → Buy
WBB Securities
More analyst ratings

$CWBR
Press Releases

Fastest customizable press release news feed in the world

See more
  • CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a "public shell," and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing requirements under Nasdaq Listing Rule 5605 and certain of Nasdaq's filing requirements under Nasdaq Listing Rule 5250(c)(1)

    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • CohBar Reports Second Quarter 2023 Financial Results

    MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. ("Morphogenesis"), for an all-stock transaction to advance a late-stage oncology pipeline. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market ("Nasdaq"). The transaction is exp

    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

    IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fa. and MENLO PARK, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology compa

    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$CWBR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CWBR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CWBR
SEC Filings

See more

$CWBR
Leadership Updates

Live Leadership Updates

See more
  • CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

    MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company's Board, effective July 11, 2022. Dr. Tozzo brings extensive research and development experience at both established pharmaceutical and innovative biotechnology companies. "We are delighted to add Dr. Tozzo to our Board and will tap into her considerable expertise in advancing preclinical assets to the clini

    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • CohBar Announces Changes to its Board of Directors and R&D Leadership

    Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBar's founders Drs. Nir Barzilai, Pinchas Cohen, and John Amatruda have transitioned from the company's Board of Directors to a reconstituted SAB. The SAB will be comprised of experts in mitochondrial science and other dis

    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

    MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry. "We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics," said David Greenwood, Chair

    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$CWBR
Financials

Live finance-specific insights

See more
  • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

    NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

    $CWBR
    $GHL
    $PDCE
    $VECT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Investment Bankers/Brokers/Service
    Finance
  • CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

    Combined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) ("CohBar" or the "company") and Morphogenesis, Inc. ("M

    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
  • CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

    MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. "I'm pleased with the team's performance during the third quarter of 2022 in advancing our top priorities, including improving the formulation of CB5138-3, our product candidate for IPF," stated Dr. Joseph Sarret, Chief Executive Officer. "We continue to operate the company i

    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$CWBR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more